List of Excipients in Branded Drug PITAVASTATIN

Generic Drugs Containing PITAVASTATIN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	pitavastatin calcium	0480-3632	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals Inc	pitavastatin calcium	0480-3632	CROSPOVIDONE
Teva Pharmaceuticals Inc	pitavastatin calcium	0480-3632	HYPROMELLOSES
Teva Pharmaceuticals Inc	pitavastatin calcium	0480-3632	LACTOSE MONOHYDRATE
Teva Pharmaceuticals Inc	pitavastatin calcium	0480-3632	MAGNESIUM OXIDE

What are the Most Frequently-Used Excipients in PITAVASTATIN?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	CROSPOVIDONE
1	HYDROXYPROPYL CELLULOSE
3	HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED
3	HYPROMELLOSE

Pitavastatin Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

Pitavastatin is a small-molecule statin marketed primarily as pitavastatin calcium. The strongest formulation opportunities are not basic generic substitution, but improved dissolution, lower-dose tablet platforms, pediatric and dysphagia-friendly presentations, fixed-dose combinations, and differentiated manufacturing processes. Commercial risk remains moderate because U.S. generic tablets are available, while regulatory exclusivity and biologic-style biosimilar barriers do not apply.

What is the FDA and commercial status of pitavastatin?

Pitavastatin calcium is an HMG-CoA reductase inhibitor approved in the United States under the brand Livalo. Kowa Pharmaceuticals America commercialized the product, which was approved by the FDA in 2009. The product is supplied as immediate-release tablets in 1 mg, 2 mg, and 4 mg strengths.[1]

Pitavastatin is indicated as an adjunct to diet for the treatment of primary hyperlipidemia and mixed dyslipidemia. The label identifies dose-dependent LDL-cholesterol reduction and recommends a usual starting dose of 2 mg once daily, with a maximum dose of 4 mg once daily.[1]

Attribute	Pitavastatin
Active ingredient	Pitavastatin calcium
Drug class	HMG-CoA reductase inhibitor
U.S. brand	Livalo
Original sponsor	Kowa
U.S. approval	2009
Dosage form	Immediate-release oral tablet
U.S. strengths	1 mg, 2 mg, 4 mg
Primary use	Hyperlipidemia and mixed dyslipidemia
Generic pathway	ANDA under Section 505(j)
Biosimilar exposure	Not applicable
Key formulation issue	Low-dose, poorly water-soluble statin formulation

Pitavastatin has a differentiated commercial position among statins because it is potent at low doses and has a relatively limited interaction profile through CYP450 pathways. Its commercial opportunity is constrained by the large generic statin market, including atorvastatin, rosuvastatin, and simvastatin.

What excipients are used in Livalo and generic pitavastatin tablets?

The Livalo label identifies a conventional tablet excipient system that supports immediate release and manufacturability. Listed inactive ingredients include lactose, low-substituted hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium aluminometasilicate, magnesium stearate, and colloidal silicon dioxide.[1]

The excipient system has four functional roles:

1. Lactose provides bulk and compressibility.
2. Low-substituted hydroxypropyl cellulose supports tablet disintegration.
3. Hydroxypropyl cellulose acts as a binder.
4. Magnesium aluminometasilicate and colloidal silicon dioxide improve powder flow and handling.
5. Magnesium stearate reduces tooling friction during compression.

The relatively low active-load profile creates an important formulation issue. A 1 mg pitavastatin tablet contains a small quantity of active ingredient relative to the total tablet mass. Blend uniformity, segregation control, and content uniformity therefore become more important than raw drug loading.

What excipient functions matter most?

Formulation function	Relevant excipient strategy	Commercial purpose
Blend uniformity	Ordered mixing, carrier-based premix, granulation	Reduces low-dose content variability
Dissolution	Wetting agents, hydrophilic polymers, particle-size control	Improves release from poorly soluble calcium salt
Disintegration	Low-substituted cellulose, crospovidone, croscarmellose sodium	Supports immediate release
Flow	Colloidal silicon dioxide, silicates	Enables high-speed tableting
Binding	Hydroxypropyl cellulose, povidone	Controls friability and compression strength
Lubrication	Magnesium stearate, sodium stearyl fumarate	Improves ejection and manufacturing robustness
Taste and swallowability	Film coating, microencapsulation, ODT excipients	Supports pediatric and dysphagia products

The excipient selection must preserve rapid disintegration without creating excessive hydrophobic lubrication. Over-lubrication with magnesium stearate can reduce tablet wetting and slow dissolution, particularly when the active ingredient already has limited aqueous solubility.

How should companies design an excipient strategy for pitavastatin?

A practical formulation program should begin with the calcium salt rather than assuming that the free-acid and salt forms behave identically. Pitavastatin calcium has pH-dependent solubility and may exhibit variable wetting and dissolution behavior depending on particle size, crystallinity, and excipient microenvironment.

Direct compression

Direct compression is commercially attractive because it minimizes processing steps and reduces manufacturing cost. It is suitable when the active pharmaceutical ingredient has acceptable flow and blend uniformity after particle engineering or ordered mixing.

A direct-compression platform may use:

• Microcrystalline cellulose for compactability.
• Low-substituted hydroxypropyl cellulose or crospovidone for disintegration.
• Colloidal silicon dioxide for flow.
• A controlled level of magnesium stearate for lubrication.
• Lactose or mannitol as a diluent.

The principal risk is segregation at the 1 mg strength. A high-shear premix, geometric dilution, or co-processed excipient system may be necessary to maintain content uniformity.

Wet granulation

Wet granulation can reduce segregation and improve compression performance. It may be preferable where the active has poor flow or where the formulation requires a narrow content-uniformity distribution.

Hydroxypropyl cellulose or povidone can provide binding. The process must control granule growth, drying temperature, residual moisture, and drug distribution. Excessive granulation can delay disintegration and reduce dissolution.

Dry granulation

Roller compaction offers a lower-moisture alternative and may support continuous manufacturing. It can improve flow and dose uniformity while avoiding water exposure. The principal risks are ribbon overcompaction, loss of tabletability, and slower disintegration after recompaction.

Solubility-enhancing systems

Pitavastatin products can be differentiated through excipient-enabled dissolution technologies, including:

• Surfactant-assisted wetting.
• Amorphous solid dispersions.
• Co-processed hydrophilic carriers.
• Nanocrystalline or micronized API systems.
• pH-modifying excipients.
• Lipid-based systems for specialized oral delivery.

These approaches require comparative dissolution and stability evidence. A formulation that improves initial dissolution but converts to a less soluble crystalline form during storage will have limited commercial value.

What formulation patents could protect pitavastatin products?

Formulation protection is more likely to arise from a specific composition or process than from the use of a common excipient alone. Patentable claim categories may include:

• A defined pitavastatin calcium particle-size distribution.
• A tablet containing a specified ratio of disintegrant, binder, and diluent.
• A formulation with enhanced dissolution under specified pH conditions.
• A solid dispersion or amorphous pitavastatin composition.
• A stable oral suspension or orally disintegrating tablet.
• A continuous-manufacturing process that controls content uniformity.
• A method for reducing degradation or polymorphic conversion.
• A fixed-dose combination containing pitavastatin and another cardiovascular agent.

A patent that claims only a broad list of conventional excipients is vulnerable to enablement, written-description, obviousness, and design-around challenges. Stronger protection typically requires a demonstrated technical effect tied to defined quantitative ranges, dissolution performance, stability, or manufacturing control.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers may include:

• Control of pitavastatin calcium particle morphology.
• Prevention of segregation at low dose.
• Reproducible granulation endpoint control.
• API-excipient compatibility.
• Moisture and heat stability.
• Scale-up of dissolution performance.
• Consistent coating weight and tablet appearance across strengths.

A commercially useful patent estate should combine composition claims with process claims. Composition claims can protect the finished product, while process claims can complicate third-party manufacturing even when a competitor uses a different excipient blend.

When did pitavastatin lose U.S. exclusivity?

Pitavastatin’s U.S. market protection was based primarily on small-molecule patent rights and regulatory exclusivity rather than biologic exclusivity. The original new-drug exclusivity period expired years before the current generic market.

The FDA approved generic pitavastatin calcium tablets through the ANDA pathway. FDA approval records identify multiple generic applicants and strengths, confirming that the product is subject to conventional generic competition rather than biosimilar competition.[2]

Protection category	Pitavastatin position
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No permanent commercial barrier
Biologic exclusivity	Not applicable
ANDA competition	Established
Paragraph IV exposure	Historically relevant during patent term
Current commercial focus	Cost, supply, formulation differentiation, and market access

The controlling patent and exclusivity information is the FDA Orange Book. Patent listings and expiration dates can change through delisting, corrections, pediatric extensions, terminal disclaimers, or litigation outcomes.[3]

What is the Orange Book status of Livalo?

Livalo is an approved small-molecule drug listed in the FDA Orange Book. Its relevant regulatory pathway is ANDA substitution, not a 351(k) biosimilar application.

Orange Book analysis should distinguish:

1. Patents listed for the reference product.
2. Patents that have expired.
3. Patents subject to pediatric extensions.
4. Patent certifications filed by ANDA applicants.
5. Any 30-month stay triggered by a Paragraph IV notice.
6. Current therapeutic-equivalence codes for approved generics.

A commercial diligence review should use the Orange Book’s active patent table and FDA approval letters rather than rely on secondary patent databases. The key issue for pitavastatin is no longer whether generic entry is legally possible. It is whether a new entrant can secure favorable pricing, distribution, or a differentiated dosage form.

Which companies are challenging or competing with pitavastatin?

Competition exists at three levels.

Generic pitavastatin manufacturers

Generic manufacturers compete through ANDA-approved tablets. Their principal advantages are lower cost and substitution through pharmacy benefit channels. Differentiation is limited unless a company obtains a distinct dosage form, strength, packaging configuration, or distribution agreement.

Competing statins

Atorvastatin and rosuvastatin dominate the broader statin market. They have extensive generic availability, broad clinical use, and substantial payer familiarity. Pitavastatin may retain opportunities in patients who require a low-dose potent statin or who have tolerability or drug-interaction considerations.

Combination-product developers

Combination products could pair pitavastatin with:

• Ezetimibe.
• Antihypertensive agents.
• Antiplatelet therapy.
• Diabetes medicines.
• Omega-3 or triglyceride-lowering agents.

The commercial case depends on clinical convenience, reimbursement, and the ability to demonstrate adherence or outcome benefits. A fixed-dose combination would also require separate regulatory and patent analysis for each active ingredient.

What commercial opportunities exist for pitavastatin excipient innovation?

The best opportunities are targeted products rather than another standard immediate-release tablet.

Orally disintegrating tablets

An ODT could address patients with dysphagia, elderly patients, and users who have difficulty swallowing conventional tablets. Mannitol, crospovidone, copovidone, and taste-masking systems are potential platform excipients. The formulation must control bitterness, friability, mouthfeel, and dose uniformity.

Pediatric formulations

A liquid suspension or dispersible tablet could expand use in pediatric hyperlipidemia, subject to clinical and regulatory requirements. Suspending agents, wetting agents, preservatives, and flavor systems would become central to development.

Sprinkle capsules or multiparticulates

Multiparticulate systems may support flexible dosing and easier administration. They also create opportunities for taste masking and controlled powder dispersion. The commercial advantage is strongest where a company can demonstrate improved adherence or administration in populations unable to swallow tablets.

High-stability tablets for emerging markets

A robust, low-cost tablet with strong humidity stability can improve distribution in markets with limited cold-chain or climate-controlled storage. Packaging, desiccant selection, and moisture-barrier film are part of the product strategy even though they may not be excipients.

Fixed-dose combinations

A pitavastatin combination product can create new intellectual-property positions through composition, ratio, dosing, and stability claims. The primary commercial barrier is reimbursement competition from inexpensive single-agent generics.

How strong is the pitavastatin patent estate?

The estate is commercially weaker for a standard immediate-release tablet than for a genuinely differentiated formulation. Core compound and original-product rights have aged, and generic entry is established. New value depends on narrow, technically supported claims.

Asset type	Relative opportunity	Main weakness
Core compound patent	Low	Mature and expired or near-expired rights
Standard tablet composition	Low to moderate	Easy excipient design-around
Particle-engineered API	Moderate	Requires reproducible technical effect
ODT or liquid formulation	Moderate to high	Smaller market and added stability burden
Fixed-dose combination	Moderate	Reimbursement and combination-development risk
Manufacturing process	Moderate	Enforcement may be difficult without access to process evidence
Packaging and stability system	Low to moderate	Limited claim scope unless tied to formulation performance

What generic launch risks exist for pitavastatin?

Generic launch risk is high for conventional tablets because multiple suppliers can compete through ANDA approval and pharmacy substitution. The main risks for a branded or differentiated product are:

• Rapid price compression.
• Therapeutic substitution by atorvastatin or rosuvastatin.
• Limited payer willingness to reimburse a premium.
• Low prescriber awareness of formulation differences.
• Small patient populations for specialized presentations.
• Difficulty proving superior adherence.
• API supply concentration.
• Patent claims that are too narrow to block design-arounds.

A new product should therefore be evaluated against net price, not list price. Commercial success is more plausible where the formulation solves a measurable administration or adherence problem.

What litigation and Paragraph IV issues affect pitavastatin?

Paragraph IV challenges are the standard mechanism for contesting listed patents before generic launch. A successful applicant can create an early-entry opportunity, while a patent owner may seek a 30-month stay under the Hatch-Waxman framework after receiving a valid notice.

For pitavastatin, the relevant diligence questions are:

• Which Orange Book patents were listed for Livalo?
• Which patents were certified by ANDA applicants?
• Did the reference sponsor file infringement litigation?
• Did any settlement provide a licensed or otherwise agreed entry date?
• Were any patent claims invalidated, narrowed, or disclaimed?
• Did any applicant launch at risk?

Patent disputes involving mature statins generally affect timing more than long-term market structure. Once several ANDA suppliers enter, price erosion and channel competition usually become the principal commercial variables.

Is biosimilar risk relevant to pitavastatin?

No. Pitavastatin is a chemically synthesized small molecule, not a biologic. Competitors use the ANDA pathway and demonstrate pharmaceutical equivalence and bioequivalence under Section 505(j), rather than biosimilarity under Section 351(k).[4]

The absence of biosimilar regulation does not reduce competition. It usually increases substitution risk because approved generics can be automatically substituted where state law and payer policy permit.

Key Takeaways

• Pitavastatin calcium is an established small-molecule statin with U.S. generic competition.
• The reference tablet uses a conventional lactose, cellulose, silicate, and magnesium stearate excipient platform.
• The central formulation challenge is low-dose content uniformity combined with dissolution control.
• Direct compression is the lowest-cost platform; wet or dry granulation may offer better process robustness.
• The strongest development opportunities are ODTs, pediatric liquids, multiparticulates, fixed-dose combinations, and high-stability products.
• Standard tablet patents are vulnerable to excipient and process design-arounds.
• Biosimilar risk does not apply; ANDA generic substitution is the relevant competitive mechanism.
• Patent value depends on demonstrable technical effects, quantitative composition limits, and process reproducibility.
• Commercial success requires a measurable advantage over inexpensive pitavastatin and other generic statins.

FAQs

Can pitavastatin be formulated without lactose?

Yes. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, and co-processed excipients can replace lactose. A lactose-free formulation may target intolerance concerns, improved moisture stability, or a specific ODT platform.

Which excipient is most important for pitavastatin dissolution?

No single excipient controls dissolution in all formulations. Wetting agents, disintegrants, particle-size reduction, hydrophilic binders, and pH-modifying excipients can each influence performance. The optimal system must be confirmed through comparative dissolution and stability testing.

Is an extended-release pitavastatin product commercially attractive?

The opportunity is technically possible but commercially uncertain. Pitavastatin is already administered once daily, so extended release must provide a distinct benefit such as improved tolerability, adherence, or pharmacokinetic control to justify development cost.

Can a new pitavastatin formulation obtain FDA approval without new clinical trials?

A conventional bioequivalent formulation may qualify through an ANDA if it meets applicable requirements. A new dosage form, route, combination, or clinically differentiated formulation may require an NDA or supplemental NDA with additional evidence.

What is the most defensible patent strategy for a pitavastatin formulation?

A layered strategy is strongest: composition claims with defined excipient ratios, particle or solid-state claims, dissolution and stability limitations, and manufacturing-process claims. Broad claims covering ordinary tablet excipients alone are more exposed to invalidity and design-around risk.

References

1. U.S. Food and Drug Administration. (2023). Livalo (pitavastatin calcium) tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, pitavastatin calcium. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application ANDA process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda/anda-process-steps-crucial-approval♀♀♀